Voyager Therapeutics

Company snapshot

Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our pr

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 31 US patent(s) indexed to this assignee profile.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Voyager Therapeutics. Not investment advice.

• Peer + 0 momentum

  Cognition Therapeutics

  TA overlap score 26.6

• Peer + 0 momentum

  vTv Therapeutics

  TA overlap score 22.8

Recent activity

Latest pipeline, patent, and corporate events for Voyager Therapeutics.

1. Jun 8, 2026 Clinical update

   Leuprolide acetate — Phase 2

2. Jun 8, 2026 Clinical update

   Intraparenchymal rAAV1 - (mi)RNA HTT — Phase 1

3. Jun 5, 2026 Clinical update

   VY7523 — Phase 2

4. Jun 5, 2026 Clinical update

   VP4896 — Phase 3

5. Sep 23, 2025 Patent grant

   AAV capsid variants and uses thereof

View all clinical trial activity →

• What is Voyager Therapeutics?

  Voyager Therapeutics is a biotech organization headquartered in Lexington, USA. It trades on NYSE under ticker VYGR. Primary therapeutic focus areas include Huntington Disease, Alzheimer Disease, Alzheimer's Disease, Alzheimer's Disease (AD). NovaPharmaNews links 4 clinical p

• Is Voyager Therapeutics publicly traded?

  Yes. Voyager Therapeutics is listed with ticker VYGR on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Voyager Therapeutics develop or market?

  We link 4 drug profile(s) where Voyager Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/voyager-therapeutics#company-drugs.

• What are the latest developments for Voyager Therapeutics?

  In the last 12 months our linked public records show 4 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does Voyager Therapeutics focus on?

  Voyager Therapeutics focuses on Huntington Disease, Alzheimer Disease, Alzheimer's Disease based on our analysis of their pipeline programs and drug development activities.